The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

SaponiQx, a leader in next-generation saponin-based adjuvant discovery and a subsidiary of Agenus Inc., today announced the publication of their latest preclinical data in the journal Vaccines. The ...

Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

The firm said it has received positive feedback from the FDA on the design of a Phase III trial of ELI-002 in KRAS-mutant pancreatic cancer.